Phytochemical Identification and Assessment of Amberboa ramosa Mediated Inhibition of Microtubule and EGFR Associated Growth and Metastasis of Breast Cancer Cells: In Vitro and In Silico Perspective

Abstract

Amberboa ramosa Roxb. (Asteraceae), commonly known as “Badaward”, has been used for the treatment of tumors from ancient times. In this study, we aimed to scientifically authenticate the use of A. ramosa for breast cancer treatment. The whole plant fractions of A. ramosa were evaluated for their cytotoxic properties against MDA-MB-231 breast cancer cell lines. Among these fractions, Pet. ether, ethyl acetate, and ethanolic fractions exhibited considerable levels of cytotoxicity against MDA-MB-231 cells with [Formula: see text] values of 78.55, 90.60, and 92.92 [Formula: see text]g/mL, respectively. The cell migration significantly decreased in ethyl acetate and ethanolic fractions. GC–MS was used to analyze the phytochemical profile of bioactive fractions, which revealed the presence of long-chain hydrocarbons, carboxylic acids, esters, alcohols, and terpenoids. Subsequently, the 96 compounds present in bioactive fractions were efficiently docked with EGFR and microtubule protein to evaluate affinity towards the targets. Eight common compounds were achieved using a docking-based approach against both target proteins, which showed similar interaction patterns as the reference inhibitors (colchicine and erlotinib). The key interactions revealed the potential of screened compounds as promising hits. 2-[1,2-Dihydroxyethyl]-9-[[Formula: see text]-d-ribofuranosyl]hypoxanthine showed the best dock score of −9.337 and −8.548 kcal/mol against EGFR and microtubule, respectively. 5-Oxo-cystofuranoquinol exhibited better dock score as well as binding energy against both targets. Chemical features present in the 08 dual inhibitors were also matched from the present EGFR and microtubule inhibitors for comparing the anticancer potential. Thus, this research revealed many new directions for developing natural lead compounds from Amberboa ramosa as dual inhibitors for treating breast cancer.